EP2016061A1 - Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin - Google Patents

Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin

Info

Publication number
EP2016061A1
EP2016061A1 EP07728463A EP07728463A EP2016061A1 EP 2016061 A1 EP2016061 A1 EP 2016061A1 EP 07728463 A EP07728463 A EP 07728463A EP 07728463 A EP07728463 A EP 07728463A EP 2016061 A1 EP2016061 A1 EP 2016061A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
methyl
imino
dihydro
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07728463A
Other languages
English (en)
French (fr)
Inventor
Daniel Marcus Bradley
Wai Ngor Chan
Stephen Harrison
Owen Hughes
David Drysdale Miller
James Neesom
Kevin Michael Thewlis
Simon Edward Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP2016061A1 publication Critical patent/EP2016061A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP07728463A 2006-04-26 2007-04-24 Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin Withdrawn EP2016061A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0608272.1A GB0608272D0 (en) 2006-04-26 2006-04-26 Compounds
PCT/EP2007/054007 WO2007122241A1 (en) 2006-04-26 2007-04-24 Compounds which potentiate ampa receptor and uses thereof in medicine

Publications (1)

Publication Number Publication Date
EP2016061A1 true EP2016061A1 (de) 2009-01-21

Family

ID=36589865

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07728463A Withdrawn EP2016061A1 (de) 2006-04-26 2007-04-24 Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin

Country Status (4)

Country Link
EP (1) EP2016061A1 (de)
JP (1) JP2009534443A (de)
GB (1) GB0608272D0 (de)
WO (1) WO2007122241A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0721092D0 (en) * 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
GB0721094D0 (en) * 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
CN102127032B (zh) * 2011-01-20 2013-03-06 北京大学 一种多取代5-酰基-2-亚胺噻唑啉的合成方法
CA2891551A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
CN105130923A (zh) * 2015-10-13 2015-12-09 浙江工业大学 一种多取代2-亚氨基噻唑类化合物的制备方法
WO2021083182A1 (zh) * 2019-10-28 2021-05-06 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL287940A (de) * 1962-01-19
JPS57197218A (en) * 1981-05-29 1982-12-03 Nippon Soda Co Ltd Central nervous system depressant containing thiazoline- 5-carboxylic acid derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007122241A1 *

Also Published As

Publication number Publication date
GB0608272D0 (en) 2006-06-07
JP2009534443A (ja) 2009-09-24
WO2007122241A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
US7566735B2 (en) Compounds which potentiate AMPA receptor and uses thereof in medicine
EP1781614B1 (de) Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin
EP1848695B1 (de) Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin
EP1786769A1 (de) Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin
EP2086643B1 (de) Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2007122241A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
EP1786766B1 (de) Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin
WO2008113795A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
WO2010066658A1 (en) Compounds which potentiate the ampa receptor and uses thereof in medicine
WO2009080637A1 (en) Compounds which potentiate the ampa receptor and uses thereof in medicine
US20090221643A1 (en) 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia
WO2009053448A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
WO2010057865A1 (en) N- inden- 2 -yl- isopropylsulfonamides as ampa receptor potentiators
WO2008148836A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
WO2009053449A1 (en) Thiazoles which potentiate ampa receptor and medicinal uses thereof
US20090170902A1 (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
WO2009092713A1 (en) Compounds which potentiate the ampa receptor and uses thereof in medicine
WO2008110566A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
WO2009092712A1 (en) Compounds which potentiate the ampa receptor and uses thereof in medicine
WO2010037760A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091031